Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

A Single-centre, Open-label, Phase I Study to Evaluate the Diagnostic Performance of 89Zirconium-labelled Girentuximab (89Zr-TLX250) PET in Urothelial Cancer Patients (ZiPUP Study) (ZiPUP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT05046665
Recruitment Status : Recruiting
First Posted : September 16, 2021
Last Update Posted : September 16, 2021
Telix International Pty Ltd
Information provided by (Responsible Party):
South Metropolitan Health Service

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : March 31, 2022
Estimated Study Completion Date : December 31, 2022